Literature DB >> 11159819

Minireview: the glucagon-like peptides.

D J Drucker1.   

Abstract

The glucagon-like peptides GLP-1 and GLP-2 are produced in enteroendocrine L cells of the small and large intestine and secreted in a nutrient-dependent manner. GLP-1 regulates nutrient assimilation via inhibition of gastric emptying and food intake. GLP-1 controls blood glucose following nutrient absorption via stimulation of glucose-dependent insulin secretion, insulin biosynthesis, islet proliferation, and neogenesis and inhibition of glucagon secretion. Experiments using GLP-1 antagonists and GLP-1 receptor-/- mice indicate that the glucoregulatory actions of GLP-1 are essential for glucose homeostasis. In the central nervous system, GLP-1 regulates hypothalamic-pituitary function and GLP-1-activated circuits mediate the CNS response to aversive stimulation. GLP-2 maintains the integrity of the intestinal mucosal epithelium via effects on gastric motility and nutrient absorption, crypt cell proliferation and apoptosis, and intestinal permeability. Both GLP-1 and GLP-2 are rapidly inactivated in the circulation as a consequence of amino-terminal cleavage by the enzyme dipeptidyl peptidase IV (DP IV). The actions of these peptides on nutrient absorption and energy homeostasis and the efficacy of GLP-1 and GLP-2 in animal models of diabetes and intestinal diseases, respectively, suggest that analogs of these peptides may be clinically useful for the treatment of human disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159819     DOI: 10.1210/endo.142.2.7983

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  89 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

2.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 3.  A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities.

Authors:  Min He; Ni Guan; Wei-wei Gao; Qing Liu; Xiao-yan Wu; Da-wei Ma; Da-fang Zhong; Guang-bo Ge; Chuan Li; Xiao-yan Chen; Ling Yang; Jia-yu Liao; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

4.  The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.

Authors:  R J Mann; N E Nasr; J K Sinfield; E Paci; D Donnelly
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice.

Authors:  Xuehong Cao; Pingwen Xu; Mario G Oyola; Yan Xia; Xiaofeng Yan; Kenji Saito; Fang Zou; Chunmei Wang; Yongjie Yang; Antentor Hinton; Chunling Yan; Hongfang Ding; Liangru Zhu; Likai Yu; Bin Yang; Yuxin Feng; Deborah J Clegg; Sohaib Khan; Richard DiMarchi; Shaila K Mani; Qingchun Tong; Yong Xu
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

6.  Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.

Authors:  Tao Ma; Xueliang Du; Joseph E Pick; Guangzhi Sui; Michael Brownlee; Eric Klann
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

7.  Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.

Authors:  S Runge; B S Wulff; K Madsen; H Bräuner-Osborne; L B Knudsen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.

Authors:  Taichi Nakamura; Tetsuhide Ito; Masahiko Uchida; Masayuki Hijioka; Hisato Igarashi; Takamasa Oono; Masaki Kato; Kazuhiko Nakamura; Koichi Suzuki; Robert T Jensen; Ryoichi Takayanagi
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

Review 9.  Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.

Authors:  Mala Dharmalingam
Journal:  Ther Adv Endocrinol Metab       Date:  2014-12       Impact factor: 3.565

10.  Amelioration of hyperglycemia by intestinal overexpression of glucagon-like peptide-1 in mice.

Authors:  Meng-Ju Liu; Jaeseok Han; Young-Sun Lee; Mi-Sung Park; Seungjin Shin; Hee-Sook Jun
Journal:  J Mol Med (Berl)       Date:  2009-12-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.